May 08, 2018 4:20pm EDT SCYNEXIS Reports First Quarter 2018 Financial Results and Provides Company Update
May 01, 2018 8:30am EDT SCYNEXIS's Oral SCY-078 Receives FDA QIDP and Fast Track Designations for the Treatment of VVC and Prevention of Recurrent VVC
Apr 23, 2018 8:00am EDT SCYNEXIS Data Presentations at ECCMID 2018 Show SCY-078 Potent and Synergistic Antifungal Activity Against Aspergillus and Pneumocystis
Apr 10, 2018 7:30am EDT SCYNEXIS to Present SCY-078 Data at the 28th European Congress of Clinical Microbiology and Infectious Disease (ECCMID)
Mar 13, 2018 4:25pm EDT SCYNEXIS Reports Full Year 2017 Financial Results and Provides Company Update
Mar 06, 2018 9:25am EST SCYNEXIS Announces Pricing of $30.0 Million Public Offering of Common Stock and Warrants
